Contents

Preface *v*
Contributors *vii*

1. Introduction to Computer-Aided Drug Design **1**
C. L. Propst and Thomas J. Perun
I. Introduction 2
II. How Drugs Are Discovered 2
III. The Basics of Mechanistic Drug Design 4
IV. Important Techniques for Drug Design 11
V. Conclusions and Future Perspectives 14
References 15

METHODS

2. Uses of Computer Graphics in Computer-Assisted Drug Design **19**
T. J. O'Donnell
I. Introduction 20
II. Computer Graphic Displays 20
III. Computed Molecular Models 25
IV. Molecular Modeling Systems for Drug Design 31
V. Uses of Computer-Assisted Drug Design 34
VI. Extending Molecular Modeling 43
References 52

3. **Theoretical Aspects of Drug Design: Molecular Mechanics and Molecular Dynamics** 55
Stanley K. Burt, Donald Mackay, and Arnold T. Hagler
I. Introduction 56
II. Potential Energy Function 58
III. Nonbonded Energy Terms 59
IV. Electrostatic Energy (V_{es})—Theoretical Considerations 62
V. Hydrogen Bonds 67
VI. Energy Minimization 70
VII. Applications of Theoretical Techniques to Drug Design 72
VIII. Future Directions 85
References 86

4. **X-Ray Crystallography and Drug Design** 93
Donald J. Abraham
I. Introduction 94
II. Methodology 94
III. Examples of Crystallographic Studies 104
IV. Hemoglobin as a Model System for Drug–Protein Interactions and Drug Design: Antisickling and Antiischemic Agents 114
V. Conclusions 122
References 124

5. **Approaches to Drug Design Using Nuclear Magnetic Resonance Spectroscopy** 133
Stephen W. Fesik
I. Introduction 133
II. Conformational Analysis 134
III. Small Molecule–Large Molecule Interactions 157
IV. Enzyme Reactions 168
V. Conclusions and Future Perspectives 172
References 173

6. **Enzyme Kinetics in Drug Design: Implications of Multiple Forms of Enzymes on Substrate and Inhibitor Structure–Activity Correlations** 185
Daniel H. Rich and Dexter B. Northrop
I. Introduction: Evidence for Multiple Forms of Enzyme 186
II. Derivation of a General Model for Enzyme–Substrate Interaction 188
III. Slow-Binding and Tight-Binding Enzyme Inhibitors 199

IV. Effects of Multiple Forms on Enzyme Inhibition: Strategies of Experimental Design and Guides for Evaluating Kinetic Data 222
V. Summary 236
Appendix 1 237
Appendix 2 242
References 244

APPLICATIONS

7. Computer-Aided Design and Evaluation of Angiotensin-Converting Enzyme Inhibitors 253
David G. Hangauer
I. Introduction 254
II. Design of Captopril with the Aid of a Conceptual Model for Angiotensin-Converting Enzyme 254
III. Molecular Mechanics-Aided Design of Conformationally Restricted Captopril Analogs 260
IV. Molecular Mechanics-Aided Design of Conformationally Restricted Enalaprilat Analogs 264
V. Computer-Aided Design of Cilazapril 271
VI. Mapping the Angiotensin-Converting Enzyme Active Site from a Conformational Analysis of Diverse Inhibitors 277
VII. Thermolysin as a Model for Angiotensin-Converting Enzyme 281
VIII. Conclusions 290
References 292

8. Role of Computer-Aided Molecular Modeling in the Design of Novel Inhibitors of Renin 297
Giorgio Bolis and Jonathan Greer
I. Introduction 298
II. Modeling of the Receptor and Substrate 301
III. Working with the Receptor–Inhibitor Model 306
IV. Applications and Examples 309
V. Conclusions 323
References 324

9. Inhibitors of Dihydrofolate Reductase 327
Lee F. Kuyper
I. Introduction 327
II. The Enzyme 328

III. Enzyme–Inhibitor Interactions 338
IV. Inhibitor Design 346
V. Conclusions 363
References 364

10. Approaches to Antiviral Drug Design **371**
Thomas J. Smith
I. Introduction 372
II. Rhinovirus as a Drug Receptor 376
III. Designing Antiviral Drugs 380
IV. Conclusions 400
References 401

11. Conformation Biological Activity Relationships for Receptor-Selective, Conformationally Constrained Opioid Peptides **405**
Victor J. Hruby and B. Montgomery Pettitt

I. Introduction 406
II. General Considerations 407
III. Design of Conformationally Constrained Delta Opioid Receptor-Selective Peptides 417
IV. Design of Conformationally Constrained μ Opioid Receptor-Selective Peptides 441
V. Problems and Prospects for Rational Design of Receptor-Selective Peptides 450
References 452

12. Design of Conformationally Restricted Cyclopeptides for the Inhibition of Cholate Uptake of Hepatocytes **461**
Horst Kessler, A. Haupt, and Martin Will
I. General Remarks 461
II. Uptake of Organic Substrates by Hepatocytes 463
III. Structure–Activity Relationships for Hepatocellular Cholate Uptake Inhibition 465
IV. Possible Applications 478
V. Conclusions 478
References 480

Index *485*